Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant

Muzaffar H. Qazilbash, Rima M. Saliba, Bilal Ahmed, Gaurav Parikh, Floralyn Mendoza, Noman Ashraf, Chitra Hosing, Thuy Flosser, Donna M. Weber, Michael Wang, Daniel R. Couriel, Uday Popat, Partow Kebriaei, Amin M. Alousi, Paolo Anderlini, Rizwan C. Naeem, Richard E. Champlin, Sergio A. Giralt

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Several chromosomal abnormalities detected by conventional cytogenetic analysis have an adverse impact on the outcome in myeloma patients. A wide spectrum of abnormalities involving chromosomes 1, 13, 14, and 17 has been described. We analyzed the outcome of 83 patients with clonal cytogenetic abnormalities, who underwent high-dose therapy and autologous stem cell transplantation for multiple myeloma at our institution. Clonal abnormalities were detected at diagnosis by conventional cytogenetic analysis in 83 patients. Patients underwent a single autologous transplant between April 2000 and May 2005. Preparative regimen was high-dose melphalan alone (73), or a combination of topotecan, melphalan, and cyclophosphamide (TMC = 10). The most commonly observed chromosomal abnormalities were deletion of chromosome 13 (32%), hyperdiploidy (21%), deletion of chromosome 1p (18%), and t (11; 14) in 7% patients. Median follow-up among surviving patients was 25.5 months. Median interval from diagnosis to autotransplant was 7.7 months (range: 2.5-52). Median progression-free survival (PFS) for the entire group was 19 months and the median overall survival (OS) was 52 months. On univariate analysis, both PFS and OS were significantly shorter in patients with deletion 1p (P = .001 and <.0001, respectively). Thirty-two patients whose cytogenetic abnormalities returned to normal prior to autotransplant had longer PFS and OS than patients with persistent abnormalities (P = .02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma.

Original languageEnglish (US)
Pages (from-to)1066-1072
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume13
Issue number9
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 1
Autografts
Chromosome Aberrations
Disease-Free Survival
Chromosomes, Human, Pair 13
Melphalan
Survival
Cytogenetic Analysis
Topotecan
Chromosomes, Human, Pair 18
Polyploidy
Stem Cell Transplantation
Multiple Myeloma
Cyclophosphamide

Keywords

  • Autotransplant
  • Chromosome abnormalities
  • Conventional cytogenetics
  • Deletion 1p
  • Multiple myeloma
  • Outcome

ASJC Scopus subject areas

  • Transplantation

Cite this

Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. / Qazilbash, Muzaffar H.; Saliba, Rima M.; Ahmed, Bilal; Parikh, Gaurav; Mendoza, Floralyn; Ashraf, Noman; Hosing, Chitra; Flosser, Thuy; Weber, Donna M.; Wang, Michael; Couriel, Daniel R.; Popat, Uday; Kebriaei, Partow; Alousi, Amin M.; Anderlini, Paolo; Naeem, Rizwan C.; Champlin, Richard E.; Giralt, Sergio A.

In: Biology of Blood and Marrow Transplantation, Vol. 13, No. 9, 09.2007, p. 1066-1072.

Research output: Contribution to journalArticle

Qazilbash, MH, Saliba, RM, Ahmed, B, Parikh, G, Mendoza, F, Ashraf, N, Hosing, C, Flosser, T, Weber, DM, Wang, M, Couriel, DR, Popat, U, Kebriaei, P, Alousi, AM, Anderlini, P, Naeem, RC, Champlin, RE & Giralt, SA 2007, 'Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant', Biology of Blood and Marrow Transplantation, vol. 13, no. 9, pp. 1066-1072. https://doi.org/10.1016/j.bbmt.2007.05.014
Qazilbash, Muzaffar H. ; Saliba, Rima M. ; Ahmed, Bilal ; Parikh, Gaurav ; Mendoza, Floralyn ; Ashraf, Noman ; Hosing, Chitra ; Flosser, Thuy ; Weber, Donna M. ; Wang, Michael ; Couriel, Daniel R. ; Popat, Uday ; Kebriaei, Partow ; Alousi, Amin M. ; Anderlini, Paolo ; Naeem, Rizwan C. ; Champlin, Richard E. ; Giralt, Sergio A. / Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. In: Biology of Blood and Marrow Transplantation. 2007 ; Vol. 13, No. 9. pp. 1066-1072.
@article{2ecc1ce80d9448e9bc2ed1e9ea5cd179,
title = "Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant",
abstract = "Several chromosomal abnormalities detected by conventional cytogenetic analysis have an adverse impact on the outcome in myeloma patients. A wide spectrum of abnormalities involving chromosomes 1, 13, 14, and 17 has been described. We analyzed the outcome of 83 patients with clonal cytogenetic abnormalities, who underwent high-dose therapy and autologous stem cell transplantation for multiple myeloma at our institution. Clonal abnormalities were detected at diagnosis by conventional cytogenetic analysis in 83 patients. Patients underwent a single autologous transplant between April 2000 and May 2005. Preparative regimen was high-dose melphalan alone (73), or a combination of topotecan, melphalan, and cyclophosphamide (TMC = 10). The most commonly observed chromosomal abnormalities were deletion of chromosome 13 (32{\%}), hyperdiploidy (21{\%}), deletion of chromosome 1p (18{\%}), and t (11; 14) in 7{\%} patients. Median follow-up among surviving patients was 25.5 months. Median interval from diagnosis to autotransplant was 7.7 months (range: 2.5-52). Median progression-free survival (PFS) for the entire group was 19 months and the median overall survival (OS) was 52 months. On univariate analysis, both PFS and OS were significantly shorter in patients with deletion 1p (P = .001 and <.0001, respectively). Thirty-two patients whose cytogenetic abnormalities returned to normal prior to autotransplant had longer PFS and OS than patients with persistent abnormalities (P = .02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma.",
keywords = "Autotransplant, Chromosome abnormalities, Conventional cytogenetics, Deletion 1p, Multiple myeloma, Outcome",
author = "Qazilbash, {Muzaffar H.} and Saliba, {Rima M.} and Bilal Ahmed and Gaurav Parikh and Floralyn Mendoza and Noman Ashraf and Chitra Hosing and Thuy Flosser and Weber, {Donna M.} and Michael Wang and Couriel, {Daniel R.} and Uday Popat and Partow Kebriaei and Alousi, {Amin M.} and Paolo Anderlini and Naeem, {Rizwan C.} and Champlin, {Richard E.} and Giralt, {Sergio A.}",
year = "2007",
month = "9",
doi = "10.1016/j.bbmt.2007.05.014",
language = "English (US)",
volume = "13",
pages = "1066--1072",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant

AU - Qazilbash, Muzaffar H.

AU - Saliba, Rima M.

AU - Ahmed, Bilal

AU - Parikh, Gaurav

AU - Mendoza, Floralyn

AU - Ashraf, Noman

AU - Hosing, Chitra

AU - Flosser, Thuy

AU - Weber, Donna M.

AU - Wang, Michael

AU - Couriel, Daniel R.

AU - Popat, Uday

AU - Kebriaei, Partow

AU - Alousi, Amin M.

AU - Anderlini, Paolo

AU - Naeem, Rizwan C.

AU - Champlin, Richard E.

AU - Giralt, Sergio A.

PY - 2007/9

Y1 - 2007/9

N2 - Several chromosomal abnormalities detected by conventional cytogenetic analysis have an adverse impact on the outcome in myeloma patients. A wide spectrum of abnormalities involving chromosomes 1, 13, 14, and 17 has been described. We analyzed the outcome of 83 patients with clonal cytogenetic abnormalities, who underwent high-dose therapy and autologous stem cell transplantation for multiple myeloma at our institution. Clonal abnormalities were detected at diagnosis by conventional cytogenetic analysis in 83 patients. Patients underwent a single autologous transplant between April 2000 and May 2005. Preparative regimen was high-dose melphalan alone (73), or a combination of topotecan, melphalan, and cyclophosphamide (TMC = 10). The most commonly observed chromosomal abnormalities were deletion of chromosome 13 (32%), hyperdiploidy (21%), deletion of chromosome 1p (18%), and t (11; 14) in 7% patients. Median follow-up among surviving patients was 25.5 months. Median interval from diagnosis to autotransplant was 7.7 months (range: 2.5-52). Median progression-free survival (PFS) for the entire group was 19 months and the median overall survival (OS) was 52 months. On univariate analysis, both PFS and OS were significantly shorter in patients with deletion 1p (P = .001 and <.0001, respectively). Thirty-two patients whose cytogenetic abnormalities returned to normal prior to autotransplant had longer PFS and OS than patients with persistent abnormalities (P = .02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma.

AB - Several chromosomal abnormalities detected by conventional cytogenetic analysis have an adverse impact on the outcome in myeloma patients. A wide spectrum of abnormalities involving chromosomes 1, 13, 14, and 17 has been described. We analyzed the outcome of 83 patients with clonal cytogenetic abnormalities, who underwent high-dose therapy and autologous stem cell transplantation for multiple myeloma at our institution. Clonal abnormalities were detected at diagnosis by conventional cytogenetic analysis in 83 patients. Patients underwent a single autologous transplant between April 2000 and May 2005. Preparative regimen was high-dose melphalan alone (73), or a combination of topotecan, melphalan, and cyclophosphamide (TMC = 10). The most commonly observed chromosomal abnormalities were deletion of chromosome 13 (32%), hyperdiploidy (21%), deletion of chromosome 1p (18%), and t (11; 14) in 7% patients. Median follow-up among surviving patients was 25.5 months. Median interval from diagnosis to autotransplant was 7.7 months (range: 2.5-52). Median progression-free survival (PFS) for the entire group was 19 months and the median overall survival (OS) was 52 months. On univariate analysis, both PFS and OS were significantly shorter in patients with deletion 1p (P = .001 and <.0001, respectively). Thirty-two patients whose cytogenetic abnormalities returned to normal prior to autotransplant had longer PFS and OS than patients with persistent abnormalities (P = .02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma.

KW - Autotransplant

KW - Chromosome abnormalities

KW - Conventional cytogenetics

KW - Deletion 1p

KW - Multiple myeloma

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=34547681819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547681819&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2007.05.014

DO - 10.1016/j.bbmt.2007.05.014

M3 - Article

C2 - 17697969

AN - SCOPUS:34547681819

VL - 13

SP - 1066

EP - 1072

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -